Payment overview · 2025
General Payments
$448.94
18 reported records · 8 companies
Healthcare provider profile · identity verified
Joel S Feiss, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Gastroenterology · PLANTATION, FL · NPI 1659344893
Verified facts
What the public records show
CMS Open Payments records show Joel S Feiss, MD received $448.94 in general payments during 2025 across 18 reported records.
Janssen Biotech, Inc. accounted for 25.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xarelto by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $112.77 | 25.1% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $96.37 | 21.5% | 4 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $65.98 | 14.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $63.49 | 14.1% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $42.62 | 9.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.64 | 5.5% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $23.66 | 5.3% | 1 | 2025 |
| Intercept Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.41 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $448.94 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $112.77 | 4 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $96.37 | 4 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $65.98 | 2 | 2025 |
Source payment records
|
|||||
| SIMPONI Normalized: simponi |
Biological | Janssen Biotech, Inc. | $51.92 | 2 | 2025 |
Source payment records
|
|||||
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $51.92 | 2 | 2025 |
Source payment records
|
|||||
| STELARA Normalized: stelara |
Biological | Janssen Biotech, Inc. | $51.92 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $42.62 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $41.25 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $41.25 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $24.64 | 1 | 2025 |
Source payment records
|
|||||
| ENTYVIO Normalized: entyvio |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $23.66 | 1 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $22.24 | 1 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $22.24 | 1 | 2025 |
Source payment records
|
|||||
| OCALIVA Normalized: ocaliva |
Drug | Intercept Pharmaceuticals, Inc. | $19.41 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $17.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 264 | 72 |
| Losartan Potassium | Losartan Potassium | 226 | 72 |
| Levothyroxine Sodium | Levothyroxine Sodium | 215 | 52 |
| Famotidine | Famotidine | 203 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 201 | 59 |
| Alprazolam | Alprazolam | 170 | 34 |
| Metformin Hcl | Metformin Hcl | 158 | 46 |
| Gabapentin | Gabapentin | 154 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 130 | 40 |
| Omeprazole | Omeprazole | 111 | 38 |
| Ezetimibe | Ezetimibe | 99 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 95 | 26 |
| Amlodipine Besylate | Amlodipine Besylate | 84 | 26 |
| Montelukast Sodium | Montelukast Sodium | 81 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 81 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 77 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 75 | 23 |
| Buspirone Hcl | Buspirone Hcl | 70 | 23 |
| Pentoxifylline | Pentoxifylline | 70 | 18 |
| Spironolactone | Spironolactone | 67 | 20 |
| Januvia | Sitagliptin Phosphate | 58 | 11 |
| Glimepiride | Glimepiride | 56 | 16 |
| Bupropion Xl | Bupropion Hcl | 53 | 11 |
| Furosemide | Furosemide | 51 | 16 |
| Simvastatin | Simvastatin | 51 | 13 |
| Mirtazapine | Mirtazapine | 49 | 25 |
| Memantine Hcl | Memantine Hcl | 47 | suppressed |
| Lorazepam | Lorazepam | 45 | 14 |
| Jardiance | Empagliflozin | 44 | suppressed |
| Lisinopril | Lisinopril | 43 | 12 |
| Temazepam | Temazepam | 43 | 15 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 42 | 16 |
| Donepezil Hcl | Donepezil Hcl | 40 | 12 |
| Fenofibrate | Fenofibrate | 40 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 40 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | 12 |
| Allopurinol | Allopurinol | 36 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 36 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 32 | 15 |
| Azithromycin | Azithromycin | 31 | 26 |
| Celecoxib | Celecoxib | 31 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 31 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 23 |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Prednisone | Prednisone | 27 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 24 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 24 | suppressed |
| Folic Acid | Folic Acid | 24 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | 12 |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 20 | suppressed |
| Eliquis | Apixaban | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Mesalamine Er | Mesalamine | 19 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Xifaxan | Rifaximin | 18 | suppressed |
| Carvedilol | Carvedilol | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 16 | suppressed |
| Meloxicam | Meloxicam | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Famciclovir | Famciclovir | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 13 |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Budesonide Dr | Budesonide | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Klonopin | Clonazepam | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Potassium Chloride | Potassium Chloride | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $448.94 · 18 records | Janssen Biotech, Inc. | CREON, DUPIXENT, ENTYVIO, IBSRELA, LINZESS, OCALIVA, RINVOQ, SIMPONI, SIMPONI ARIA, SKYRIZI, STELARA, TREMFYA, VIBERZI, Wegovy, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error